Royalty Report: Drugs, Cancer, Disease – Collection: 74574

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 19

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 19

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Biotechnology
  • cell therapy
  • Antibody
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 74574

License Grant
This letter of intent with a Chinese Licensor is for Super Antigen Receptor T cell (CAR-T) cocktail therapy, patents pending, manufacturing technology, and clinical data of the aforementioned therapies.
License Property
CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack cancer tumors.
Field of Use
The Super CAR –T Cocktail therapy has shown promise in early human clinical trials for the treatment of blood cancer, renal, cervical and hepatic cancer.

IPSCIO Record ID: 256489

License Grant
The Company has agreed to pay Licensor a royalty of the net sales derived from two specified CAR-T products.
License Property
CAR-T products are therapies, which are genetically engineered synthetic receptors that recognize a specific antigen expressed on tumor cells.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 262605

License Grant
The Licensor, a not-for-profit corporation formed to hold, manage, and facilitate commercialization of the university's intellectual property, grants the French Licensee a royalty-bearing exclusive license under Patent Rights to use, develop, manufacture, market, and commercialize the Licensed Subject Matter in the field of Cancer Immunotherapy, including right to use the Patent 2014/036684 – CSI-Specific chimeric Antigen Receptor Engineered Immune Cells and Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cells for Cancer Immunotherapy.
License Property
Licensed Subject Matter is Cancer Immumotherapy, including US Patent United States Patent 10,227,409 granted March 12, 2019.
Field of Use
The Licensee is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.

IPSCIO Record ID: 415

License Grant
The Company acquired the intellectual property rights relating to certain combination immunogene therapy technology from Licensor, an individual.
License Property
The technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025.  The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells.  The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF.  Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 312594

License Grant
Licensors filed a complaint against Licensee in the U.S. District Court for the Central District of California. The complaint alleged that Yescarta* infringes certain claims of U.S. Patent No. 7,446,190 concerning CAR T cell technologies.

In April 2020, the Court granted in part Licensor’s motion and entered a final judgment awarding royalties on Licensee’s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.

License Property
CAR T refers to cell therapy.

Yescarta is a trademark of Licensee.   Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patient’s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.

Field of Use
Yescarta is cell therapy used in the treatment of cancer.  Licensee is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.

IPSCIO Record ID: 203444

License Grant
The Canadian Licensor grants to the Israeli Licensee an exclusive, even as to Licensor, right and license throughout the Territory, with the right to grant sublicenses, under the Licensor Intellectual Property
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan,  to conduct the Licensor Clinical Studies,  subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.

The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.

Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.

License Property
The licensed property includes
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.

The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.

Field of Use
The Field means the prevention, diagnosis or treatment of any disease or medical condition in humans.  Specific fields addressed in the patents include prostate cancer cells, human renal cell cancer (RCC) cells and some breast cancer cells.

IPSCIO Record ID: 7355

License Grant
Under the joint venture arrangement the Licensee holds an exclusive License to develop and market Cancer (TC-DC), Motor Neuron Precursor Cells (MNP) and Neuronal Precursor Cells (NP) in greater China and Taiwan.
License Property
These methodologies enable the Licensee to conduct certain clinical trials and commercialization. The TC-DC therapy utilizes dendritic cells that have been taught the unique 'signature' of the patient's cancer, in order to trigger an effective immune response against cancer stem cells, the root cause of cancer metastasis and recurrence.
Field of Use
The Licensee has a process to develop MNP and NP cells with high purity levels, validated by synapse formation, and have shown functional innervation with human muscle cells. These products enable us to conduct certain clinical trials and pursue commercialization for TC-DC, and explore the development of new therapies for a variety of neurodegenerative diseases.

IPSCIO Record ID: 246211

License Grant
The Licensor hereby grants to the Licensee an exclusive, worldwide, royalty-bearing license under Licensors rights in the Licensed Technology to make, develop, use, sell, offer for sale and import Licensed Products in the Field. Such license shall include the right to grant sublicenses. The IP is a proprietary biological molecule that inhibits soluble tumor necrosis factor.
License Property
The Licensor has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor.

INB03 is a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells.

Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.

Field of Use
Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 336552

License Grant
Licensor of United Kingdom, whose key founders are also shareholders of the Licensee, pursuant to which the Licensee obtained a worldwide license to Licensor’s proprietary technology, know-how and intellectual property for the research, development and manufacture of TIL therapies obtained from tumors using Licensor’s technology.
License Property
TIL are tumor infiltrating lymphocyte therapies.

Tumor-infiltrating lymphocytes are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, (i.e., T cells, B cells, natural killer cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, basophils, etc.) in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis

Field of Use
Tumor infiltrating lymphocyte or TIL is therapies for the treatment of patients with cancer.

IPSCIO Record ID: 318779

License Grant
In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Option Agreements were terminated and a royalty payment from the sale of IRX-2 was agreed upon to the Collaborator for a period of time.
License Property
IRX-2 is a novel cytokine-based therapy. IRX-2 active constituents, namely Interleukin-2 (IL-2) and other key cytokines are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. IRX-2 is naturally derived from human blood cells.

IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.
IRX-2 is produced under current good manufacturing practices, or cGMP, following stimulation of a specific population of human peripheral blood mononuclear cells (PMBC) using a specified mitogen. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes. Cytokine production induced by the employed mitogen mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. PBMCs are obtained from FDA-licensed blood banks meeting all criteria for further human use.

Field of Use
The field of use is for the treatment of cancer relating to advanced head and neck squamous cell cancer.

The Licensee is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer.

IPSCIO Record ID: 362483

License Grant
Licensors, as applicable, grant to Licensee of Switzerland an exclusive, sub-licensable license, under the Licensor IP in the Territory in the Field,
–  to generate and test Chimeric Antigen Receptor T-Cell Products solely for the Development, Regulatory Approval and Commercialization of Products containing such Chimeric Antigen Receptor I-Cell Products;
–  to Develop and Commercialize Products in the Field in the Territory, provided that such Products are not Out-of-Scope Products; and
–  to Commercialize the Chimeric Antigen Receptor for Products.
License Property
Licensor has expertise in and owns or controls proprietary technology relating to genetically engineering cells to target and destroy cancer cells.

Product means any pharmaceutical product containing a Chimeric Antigen Receptor I-Cell Product developed by Licensor under a Research Program for which the JSC determines to file an IND or under a research program for which Licensee has exercised the Licensor Program Option, or, any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Licensee that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described above.

Allogcneic Cell Therapy means a genomically engineered patient-nonspecific T-cell expressing a Chimeric Antigen Receptor for delivery to a patient developed under the Allogeneic Cell Therapy Research Program satisfying the Allogeneic Cell Therapy Criteria.

Chimeric Antigen Receptor T-Cell Product means a T-Cell having a Chimeric Antigen Receptor, or, a T-cell under switch control having a Chimeric Antigen Receptor and any Activator Ligands or Exclusive Activator Ligands that are administered to control such T-cells irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such T-cell directed to a Target, or, an Allogeneic Cell Therapy, or, the Allogeneic Cell Therapy under switch control having a Chimeric Antigen Receptor directed to a Target and any Activator Ligands or Exclusive Activator Ligands that are administered to control such Allogeneic Cell Therapy irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such Allogeneic Cell Therapy, or, any component sold as a kit, such as a device, delivery system or therapy scheme for the above to modify such T-cell including one or more polypeptides or nucleic acids encoding a CAR.

Licensor Platform Technology means Licensors platform of research tools and technology necessary for Licensor to perform its tasks directed towards the design, identification, culturing, and/or production of genetically modified cells consistent with this Agreement, including without limitation the technology embodied in the Licensor Materials and the Licensor Patents, and specifically including without limitation the following of Licensors platform areas and capabilities
(I) UltraVcctor,
(2) LEAP,
(3) DNA and RNA MOD engineering,
(4) protein engineering,
(5) transcription control chemistry,
(6) genome engineering,
(7) cell system engineering,
(8) Endometrial Regenerative Cells,
(9) the RheoSwitchE technology and RheoSwitch Therapeutic Systems, and
(10) MD Anderson CC Technologies.

Field of Use
The Field means the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans.

IPSCIO Record ID: 256217

License Grant
In the original agreement Licensor, government public health organization, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.

The Licensor grants a co-exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use. For purposes of this Agreement co-exclusive shall mean that at any time only the Licensee and its Affiliates, on the one hand, and one other Licensee and its Affiliates, on the other hand, shall at any time have a license or other right from the Licensor under the Licensed Patent Rights in the Licensed Territory in the Licensed Fields of Use.

License Property
The agreement is for a specified constructs, formulations and doses of specified Licensed Products in a specified cancer indication, the statistical demonstration in a pivotal Phase 3 Clinical Study of safety and efficacy, sufficient to support a BLA submission by the Licensee for such specified construct, formulation and dose of such specified Licensed Product for the treatment of such specified cancer indication.
Field of Use
Licensed Fields of Use, defined in the original agreeement is
–  Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of head and neck cancer, hepatocellular carcinoma, melanoma, prostate cancer, and sarcoma.
–  Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of brain cancer, head and neck cancer, and melanoma.
–  Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
–  Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
For purposes of the Agreement, autologous peripheral blood T cell therapy products shall mean T cell or precursor products and compositions derived from blood, bone marrow, lymph nodes and thymus and, for the avoidance of doubt, shall exclude tumor-infiltrating lymphocytes (TILs).

IPSCIO Record ID: 248290

License Grant
This amendment modifies the list of patents and adds sublicense clarifications. For clarity,  sales of Licensed Products by Licensee or its Affiliate to a Sublicensee for resale by such Sublicensee are not included in Net Sales,  sales of Licensed Products by a Sub licensee (including those Licensed Products purchased from Licensee or its Affiliates) to a Third Party that is not an Affiliate of such Sublicensee are included in Net Sales, and in the event that Licensee or an Affiliate of Licensee grants rights.
License Property
The amended list of patents include, but are not limited to Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase;  Method for Tumor Treatment Using Infusion of Xenogeneic Cells to Induce Hyperacute Rejection and Innocent Bystander Effect;  Methods and Comp__ositions for Inducing Complement Destruction of Tissue;  and,  Herpes SimJ!lex Virus Amplicon Mini-Vector Gene Transfer System.
Field of Use
The patents are for cell therapies for tumor treatment.

IPSCIO Record ID: 302213

License Grant
Licensor granted to Chinese Licensee an exclusive, sublicensable, royalty-bearing license to Licensor’s patents and know-how to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement.
License Property
Enoblituzumab is the Most Advanced Clinical Stage Humanized B7-H3 Antibody as a Potential Immuno-oncology Treatment.  This is a Fc-optimized antibody that targets B7-H3, including in combination with other agents, such as the anti-PD-1 antibody known as MGA012.

Enoblituzumab is a humanized antibody directed at B7-H3, a member of the B7 family of T cell checkpoint regulators. B7-H3 is a promising immuno-oncology drug target as it is widely expressed across multiple tumor types and plays a key role in regulating immune response against cancers. Increasing pre-clinical and clinical evidence suggests that antibodies targeting the two T cell checkpoint molecules—B7-H3 and PD-1—work synergistically in treating cancer. Given B7-H3’s critical role, enoblituzumab has a wide range of cancer applications as either a monotherapy or in combination with PD-1 therapies. At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function and is at the forefront in global clinical development. Originally developed by Licensor, enoblituzumab has been evaluated in multiple clinical trials as a monotherapy or in combination with CTLA-4 or PD-1 therapies in patients with B7-H3-expressing cancers. Enoblituzumab is also being evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate cancer.

Field of Use
The license granted is used as an immuno-oncology drug target playing a key role in regulating immune response against cancers.

Licensee and its subsidiaries are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China (the “PRC”) and other countries and regions.

IPSCIO Record ID: 359135

License Grant
Licensor entered into a license agreement with Chinese Licensee, thereby granting to Licensee exclusive rights to commercialize Licensor's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.
License Property
Pritumumab, a drug candidate using monoclonal antibodies for the treatment of various cancer types. Pritumumab may offer an advantage over existing treatments. Pritumumab works by binding to a target on the surface of cancer cells called ectodomain vimentin (also referred to as cell-surface vimentin). The target, generally referred to as an antigen, is prevalent in many different tumor types and is not being targeted by any other biopharmaceutical companies. By binding to this target, Pritumumab is able to make the tumor cells “known” to the body’s immune system, resulting in potentially several types of immune responses, including anti-idiotype, apoptosis, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to death of the cancer cells and overall depletion of the tumor.
Field of Use
Field of use is for the treatment of brain cancer and pancreatic cancer and exploring in its use against viruses.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.

IPSCIO Record ID: 256873

License Grant
The Taiwanese Licensor hereby grants sole licensing rights to Licensee, a shareholder, in the Field and in the Territory under the Intellectual Property, Confidential Information, Data and Trademark, to develop Product.
License Property
Drug and therapeutic use of five products BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia
The new drug products that originate from Maitake Combination Therapy. The three drugs licensed from BriVision to Rgene are ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy.
Field of Use
Maitake Combination Therapy for indications including but not limited to the following breast cancer, brain tumor, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, nasopharyngeal carcinoma, prostate cancer, cervix cancer, oral/ pharynx/larynx cancer, lung cancer, leukemia, myeloma, lymphoma, gastric cancer, thyroid cancer, esophageal cancer, gastric cancer, small intestine cancer, large intestine/colon/rectal cancer, ovary cancer, skin cancer, head and neck, soft tissue sarcoma, bone tumor, bladder cancer, and cholangiocarcinomab.”

IPSCIO Record ID: 28485

License Grant
The Licensee entered into an exclusive, worldwide License Agreement with a University for the AC Technology.
License Property
The AC Technology is based on the concept of haptenization.  

Our AC Technology utilizes the patient's tumor as the basis for a therapeutic vaccine.  By collecting and processing the cancer cells extracted from a patient's tumor most typically during the course of the first line of treatment, surgical tumor rescission, and then treating them with a hapten called dinitrophenol ('DNP'), a vaccine is prepared and then given back to the patient in an effort to elicit a systemic immune response to the unmodified, native cancer cells.

Field of Use
The Licensee is a development stage biotechnology company specializing primarily in the development and future commercialization of individualized cancer vaccines.  Our proposed vaccines consist of autologous (the patient's own) cancer cells that have been treated with a chemical ('haptenized') to make them more visible to the patient's immune system.  Our previous clinical trials for the AC Vaccine have concentrated on melanoma and ovarian carcinoma, which are our primary indications, and non-small cell lung cancer.

IPSCIO Record ID: 246212

License Grant
The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.
License Property
Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled  â€œIn vivo activation of natural killer cells'.

Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS

NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for antigen presentation, which is why they are called “natural killers.”

Field of Use
The term “Field” or “Field of Use” shall mean all applications of the Patent Rights.  Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.

Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.